Healing & Repair
AHK-Cu
← Back to Library
Site-only / unverified Site-only / unverified Site-only / unverified Aesthetics Repair
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 50 mg
Dosing window: Anytime
Receptor / target: Endothelial Cells
Properties: Not stated
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 1.0mg to 2.0mg daily | Subcutaneous for systemic effect. |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (Endothelial Cells); route Subcutaneous; timing Anytime. Site-only/low dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Site-provided dosing remains unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Wilson's disease or other genetic copper metabolism disorders: the injectable copper complex bypasses normal hepatic copper handling; contraindicated in any subject with impaired copper transport. Site-only / unverified
- Known copper hypersensitivity or copper allergy: systemic injection may provoke significant immune/inflammatory reactions in copper-sensitive individuals. Site-only / unverified
- Active malignancy: AHK-Cu promotes endothelial cell proliferation and angiogenesis; in the context of active cancer these mechanisms could support tumor vascularization. Site-only / unverified
- Pregnancy: no human safety data; copper homeostasis is critical during fetal development. Site-only / unverified
- Breastfeeding: no established safety data. Site-only / unverified
- Known hypersensitivity to AHK-Cu or peptide excipients. Site-only / unverified
- Concurrent use of copper-chelating agents (e.g., penicillamine, trientine, high-dose zinc): will competitively neutralize the copper complex. Site-only / unverified
- Elevated baseline serum copper levels or hemochromatosis: impaired metal homeostasis increases copper toxicity risk at injectable doses. Site-only / unverified
Side effects (site-sourced)
- Severe Post-Injection Pain (PIP) and welting: the primary and expected adverse effect of subcutaneous AHK-Cu; burning, stinging, redness, and local welt formation at the injection site; copper ion-mediated; identical in mechanism to GHK-Cu PIP; mitigated by co-injection with BPC-157 and frequent site rotation. Site-only / unverified
- Bruising and localized hematoma: common with daily administration; the 8-week cycle with rotation manages but does not eliminate this. Site-only / unverified
- Local induration and redness: tissue copper deposition response; self-resolving between injections. Site-only / unverified
- Copper toxicity at excessive doses: abdominal pain, metallic taste, nausea, vomiting, weakness, anemia; not expected at standard protocol doses but a risk with chronic accumulation. Site-only / unverified
- Transient local hyperpigmentation: tyrosinase activation from copper delivery can produce pigment changes at injection sites; typically reversible. Site-only / unverified
- Nausea: rare; copper-related at higher doses. Site-only / unverified
- Headache: uncommon. Site-only / unverified
- Mild systemic fatigue: reported in early weeks; related to angiogenic and remodeling signal activation. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.